Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FSME-IMMUN TBE Antibody Persistence and 2nd Booster
NCT01582698Phase 4Completed
- Sponsor
- Pfizer
- Start
- Apr 2012
- Primary completion
- Jun 2015
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
A Phase 4 trial of FSME-IMMUN in tick-borne encephalitis (TBE), sponsored by Pfizer. Started Apr 2012; status: completed.
02
Drugs
FSME-IMMUN
03
Conditions
tick-borne encephalitis (TBE)
Beyond the preview
Go deeper on NCT01582698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01582698.